T.
ROWE
PRICE
Health
Sciences
Fund
March
31,
2026
Unaudited
1
Portfolio
of
Investments
Shares/Par
$
Value
(Cost
and
value
in
$000s)
COMMON
STOCKS
 95.0%
BIOTECHNOLOGY
 39.8%
International-Biotechnology
 0.1%
Ideaya
Biosciences (1)
259,143‌
8,635‌
8,635‌
Major
Biotechnology
 8.1%
Amgen 
303,722‌
106,864‌
Celldex
Therapeutics (1)
422,316‌
13,396‌
Exact
Sciences
CMO
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
3,726,272‌
—‌
Exact
Sciences
FDA
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
1,863,136‌
—‌
Gilead
Sciences 
2,034,836‌
283,595‌
Royalty
Pharma,
Class
1,241,743‌
59,566‌
United
Therapeutics (1)
255,863‌
151,722‌
Vertex
Pharmaceuticals (1)
591,295‌
264,037‌
879,180‌
Other
Biotechnology
 31.6%
Abivax,
ADR (1)
427,254‌
47,575‌
Affinivax
Expense
Fund,
Acquisition
Date:
9/12/22,
Cost $13 (1)
(2)(3)
12,445‌
11‌
Affinivax
Milestone
Event,
Acquisition
Date:
9/12/22,
Cost $3,454 (1)(2)(3)
7,349,672‌
—‌
Affinivax
Next
Gen.
Prod.
Milestone
Event,
Acquisition
Date:
9/12/22,
Cost $3,454 (1)(2)(3)
7,349,672‌
—‌
Agios
Pharmaceuticals (1)
70,221‌
2,376‌
Aktis
Oncology (1)
333,745‌
5,971‌
Aktis
Oncology,
Lockup
Shares,
Acquisition
Date:
9/20/24,
Cost $11,032 (1)(3)
724,914‌
12,969‌
Allogene
Therapeutics (1)
3,830,998‌
9,348‌
Alnylam
Pharmaceuticals (1)
538,254‌
178,092‌
Annexon (1)
176,618‌
978‌
Apogee
Therapeutics (1)
555,098‌
46,723‌
Argenx,
ADR (1)
449,830‌
328,488‌
Ascendis
Pharma,
ADR (1)
699,373‌
159,968‌
Atrium
Therapeutics (1)
666,325‌
8,909‌
Aura
Biosciences (1)
221,135‌
1,479‌
Axsome
Therapeutics (1)
157,710‌
26,656‌
Beam
Therapeutics (1)
1,184,792‌
28,234‌
BeOne
Medicines,
ADR (1)
49,225‌
14,618‌
BeOne
Medicines,
Class
H
(HKD) (1)
5,757,796‌
129,161‌
Bicara
Therapeutics (1)
642,514‌
12,780‌
T.
ROWE
PRICE
Health
Sciences
Fund
2
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Bicycle
Therapeutics,
ADR (1)
739,251‌
3,430‌
Biohaven (1)
1,228,554‌
10,394‌
BridgeBio
Oncology
Therapeutics (1)
333,485‌
2,985‌
Bridgebio
Pharma (1)
864,149‌
64,172‌
Cabaletta,
Warrants,
9/20/26,
Acquisition
Date:
6/11/25,
Cost $— (1)(3)
1,694,355‌
322‌
Cabaletta
Bio (1)
371,687‌
1,000‌
CG
oncology (1)
1,186,673‌
80,314‌
Climb
Bio (1)
1,468,417‌
10,059‌
Crescent
Biopharma (1)
221,065‌
4,061‌
Crinetics
Pharmaceuticals (1)
1,152,256‌
41,850‌
Cytokinetics (1)
633,400‌
41,747‌
Denali
Therapeutics (1)
468,129‌
8,988‌
Disc
Medicine (1)
186,605‌
11,931‌
Eikon
Therapeutics (1)
349,098‌
3,693‌
Eikon
Therapeutics,
Lockup
Shares,
Acquisition
Date:
12/3/21
-
2/14/25,
Cost $27,689 (1)(3)
371,442‌
3,930‌
Entrada
Therapeutics (1)
329,233‌
4,155‌
Evommune
PIPE,
Acquisition
Date:
2/13/26,
Cost $3,496 (1)(3)
125,397‌
2,739‌
Generate
Biomedicines (1)
291,644‌
3,645‌
Generate
Biomedicines,
Lockup
Shares,
Acquisition
Date:
9/2/21
-
5/9/23,
Cost $26,508 (1)(3)
1,472,673‌
18,408‌
Generation
Bio (1)(2)
102,601‌
—‌
Ginkgo
Bioworks,
Earn
Out
Shares
$15.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(2)(3)
5,317‌
—‌
Ginkgo
Bioworks,
Earn
Out
Shares
$17.50,
Acquisition
Date:
9/17/21,
Cost $— (1)(2)(3)
5,317‌
—‌
Ginkgo
Bioworks,
Earn
Out
Shares
$20.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(2)(3)
5,317‌
—‌
Gyroscope
Therapeutics,
Milestone
Payment
1,
Acquisition
Date:
2/18/22,
Cost $5,684 (1)(2)(3)
5,683,928‌
—‌
Gyroscope
Therapeutics,
Milestone
Payment
2,
Acquisition
Date:
2/18/22,
Cost $3,788 (1)(2)(3)
3,788,007‌
—‌
Gyroscope
Therapeutics,
Milestone
Payment
3,
Acquisition
Date:
2/18/22,
Cost $3,788 (1)(2)(3)
3,788,007‌
—‌
Immunocore
Holdings,
ADR (1)
715,068‌
21,559‌
Immunome (1)
1,764,714‌
38,594‌
Incyte (1)
405,040‌
38,122‌
Insmed (1)
722,295‌
118,110‌
Ionis
Pharmaceuticals (1)
882,823‌
66,291‌
Iovance
Biotherapeutics (1)
2,047,047‌
7,185‌
Krystal
Biotech (1)
281,651‌
72,756‌
Kymera
Therapeutics (1)
1,065,867‌
88,776‌
Kyverna
Therapeutics (1)
1,142,161‌
9,857‌
T.
ROWE
PRICE
Health
Sciences
Fund
3
Shares/Par
$
Value
(Cost
and
value
in
$000s)
MBX
Biosciences (1)
757,109‌
22,600‌
MediWound (1)
62,181‌
1,002‌
Mirum
Pharma
Escrow
Expense
Fund,
EC,
Acquisition
Date:
2/4/26,
Cost $48 (1)(2)(3)
48,097‌
46‌
Mirum
Pharma
Escrow
Indemnity,
EC,
Acquisition
Date:
2/4/26,
Cost $1,193 (1)(2)(3)
1,192,808‌
1,133‌
Mirum
Pharma
Escrow
Working
Capital,
EC,
Acquisition
Date:
2/4/26,
Cost $48 (1)(2)(3)
48,097‌
46‌
Mirum
Pharma
Indemnity
Holdback,
Acquisition
Date:
2/4/26,
Cost $1,789 (1)(3)
25,126‌
2,205‌
Mirum
Pharma
Milestone
$500
Million,
Acquisition
Date:
2/4/26,
Cost $— (1)(2)(3)
3,428,195‌
—‌
Mirum
Pharma
Milestone
$750
Million,
Acquisition
Date:
2/4/26,
Cost $— (1)(2)(3)
5,713,658‌
—‌
Mirum
Pharma,
Lockup
Shares
6
Month,
Acquisition
Date:
2/4/26,
Cost $8,003 (1)(3)
112,393‌
9,864‌
Mirum
Pharma,
Lockup
Shares
9
Month,
Acquisition
Date:
2/4/26,
Cost $8,003 (1)(3)
112,393‌
9,864‌
Moderna (1)
194,190‌
9,865‌
Monte
Rosa
Therapeutics (1)
1,998,210‌
32,870‌
MoonLake
Immunotherapeutics (1)
1,001,029‌
18,659‌
Natera (1)
561,746‌
112,344‌
Nuvalent,
Class
A (1)
480,891‌
49,267‌
Odyssey
Therapeutics,
Warrants,
6/16/32,
Acquisition
Date:
6/16/25,
Cost $— (1)(2)(3)
133,346‌
—‌
ORIC
Pharmaceuticals (1)
1,740,383‌
22,051‌
Oruka
Therapeutics (1)
519,918‌
25,502‌
Pharvaris (1)
331,529‌
9,366‌
Praxis
Precision
Medicines (1)
189,301‌
60,991‌
ProfoundBio,
Escrow
Fund
Payment,
EC,
Acquisition
Date:
5/24/24,
Cost $705 (1)(2)(3)
704,486‌
669‌
ProfoundBio,
Expense
Fund
Payment,
EC,
Acquisition
Date:
5/24/24,
Cost $2 (1)(2)(3)
2,348‌
—‌
Protagonist
Therapeutics (1)
1,162,259‌
122,502‌
Rapport
Therapeutics (1)
636,405‌
19,913‌
Regeneron
Pharmaceuticals 
380,026‌
293,623‌
Relay
Therapeutics (1)
1,299,962‌
12,935‌
Repligen (1)
108,730‌
12,811‌
Replimune
Group (1)
1,427,764‌
10,922‌
Revolution
Medicines (1)
1,519,722‌
147,793‌
Revolution
Medicines,
Warrants,
11/14/28 (1)
198,505‌
345‌
Rhythm
Pharmaceuticals (1)
241,658‌
21,017‌
Ring
Therapeutics,
Acquisition
Date:
4/12/21
-
10/7/22,
Cost $13,418 (1)(2)(3)
291,704‌
1,342‌
Rocket
Pharmaceuticals (1)
464,628‌
1,663‌
T.
ROWE
PRICE
Health
Sciences
Fund
4
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Roivant
Sciences (1)
4,562,773‌
126,389‌
Scholar
Rock
Holding (1)
1,521,080‌
74,776‌
Sensorion
(EUR) (1)
17,215,766‌
8,174‌
Sionna
Therapeutics (1)
574,043‌
23,013‌
Spyre
Therapeutics (1)
897,045‌
45,247‌
Structure
Therapeutics,
ADR (1)
1,318,007‌
63,528‌
Summit
Therapeutics (1)
6,177,431‌
117,124‌
Tarsus
Pharmaceuticals (1)
175,856‌
12,336‌
Tenax
Therapeutics (1)(4)
2,543,505‌
40,671‌
Treeline
Biosciences,
Warrants,
8/21/35,
Acquisition
Date:
8/21/25,
Cost $— (1)(2)(3)
44,917‌
327‌
Vaxcyte (1)
278,645‌
16,192‌
Vera
Therapeutics (1)
1,315,706‌
52,931‌
Viridian
Therapeutics (1)
343,846‌
6,726‌
WaVe
Life
Sciences (1)
2,253,333‌
16,337‌
Xencor (1)
378,576‌
4,566‌
Zai
Lab,
ADR (1)
213,174‌
4,010‌
3,438,966‌
Total
Biotechnology
4,326,781‌
CONSUMER
NONDURABLES
 3.2%
Pharmaceuticals
 3.2%
AstraZeneca 
1,751,235‌
345,379‌
Total
Consumer
Nondurables
345,379‌
LIFE
SCIENCES
 6.4%
Life
Sciences
 6.4%
Charles
River
Laboratories
International (1)
79,633‌
13,737‌
Chromacode,
Acquisition
Date:
2/28/22,
Cost $4,393 (1)(2)(3)
626‌
3‌
Danaher 
1,175,471‌
222,869‌
Ginkgo
Bioworks
Holdings (1)
23,550‌
144‌
Revvity 
214,677‌
18,808‌
SomaLogic,
Warrants,
8/31/26 (1)
90,179‌
—‌
Thermo
Fisher
Scientific 
900,979‌
442,858‌
Total
Life
Sciences
698,419‌
PHARMACEUTICALS
 19.9%
Major
Pharmaceuticals
 19.6%
AbbVie 
1,423,341‌
309,562‌
Chugai
Pharmaceutical
(JPY) 
1,237,800‌
68,263‌
Eli
Lilly 
1,200,478‌
1,104,164‌
Johnson
&
Johnson 
1,088,355‌
266,038‌
Merck 
3,116,392‌
374,871‌
T.
ROWE
PRICE
Health
Sciences
Fund
5
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Novo
Nordisk,
ADR 
446,869‌
16,422‌
2,139,320‌
Specialty
Pharmaceuticals
 0.3%
Blue
Marlin
Therapeutics,
Acquisition
Date:
12/18/25,
Cost $— (1)(2)(3)
1,803‌
—‌
Madrigal
Pharmaceuticals (1)
70,723‌
37,022‌
37,022‌
Total
Pharmaceuticals
2,176,342‌
PRODUCTS
&
DEVICES
 9.4%
Capital
Equipment
 0.1%
PROCEPT
BioRobotics (1)
289,633‌
7,244‌
7,244‌
Implants
 8.5%
Boston
Scientific (1)
1,267,771‌
79,553‌
Edwards
Lifesciences (1)
562,277‌
45,027‌
Intuitive
Surgical (1)
863,221‌
397,936‌
Sonova
Holding
(CHF) 
105,533‌
24,063‌
Stryker 
1,147,522‌
377,064‌
Verily
Life
Sciences,
Series
B,
Acquisition
Date:
1/23/19,
Cost $13,998 (1)(2)(3)
113,564‌
1,266‌
924,909‌
Other
Products
&
Devices
 0.8%
Celcuity (1)
540,300‌
61,670‌
IDEXX
Laboratories (1)
1,232‌
692‌
Kestra
Medical
Technologies (1)
744,410‌
14,836‌
Pax
Labs,
Class
A,
Acquisition
Date:
4/18/19,
Cost $31,623 (1)
(2)(3)
8,397,988‌
2,604‌
Saluda
Medical,
CDI
(AUD) (1)
3,958,452‌
2,275‌
Saluda
Medical,
Warrants,
3/14/35,
Acquisition
Date:
1/20/22,
Cost $0 (1)(2)(3)
2‌
—‌
Saluda
Medical,
Lockup
Shares,
CDI,
Acquisition
Date:
1/20/22
-
11/4/25,
Cost $14,874
(AUD) (1)(3)
3,715,230‌
2,102‌
84,179‌
Total
Products
&
Devices
1,016,332‌
SERVICES
 11.5%
Distribution
 2.2%
Cardinal
Health 
348,232‌
73,585‌
Cencora 
179,717‌
56,456‌
CVS
Health 
1,310,339‌
94,109‌
McKesson 
24,522‌
21,220‌
245,370‌
T.
ROWE
PRICE
Health
Sciences
Fund
6
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Information
 0.0%
GeneDx
Holdings,
Warrants,
7/22/26 (1)
206,747‌
2‌
2‌
Other
Services
 1.3%
Caris
Life
Sciences (1)
2,029,167‌
36,281‌
Guardant
Health (1)
1,055,988‌
97,542‌
Perceptive
Capital
Solutions
SPAC/Freenome
Holdings
PIPE (1)(5)
438,178‌
4,326‌
PrognomIQ,
Class
A,
Acquisition
Date:
11/15/19
-
4/22/25,
Cost $14,562 (1)(2)(3)
606,647‌
91‌
138,240‌
Payors
 5.0%
Alignment
Healthcare (1)
1,475,585‌
26,000‌
Centene (1)
529,331‌
17,330‌
Cigna
Group 
300,304‌
80,106‌
Elevance
Health 
244,278‌
71,512‌
Molina
Healthcare (1)
85,655‌
11,418‌
UnitedHealth
Group 
1,242,865‌
336,307‌
542,673‌
Providers
 3.0%
BrightSpring
Health
Services (1)
2,514,077‌
107,125‌
Encompass
Health 
151,360‌
14,641‌
HCA
Healthcare 
206,215‌
97,589‌
Tenet
Healthcare (1)
580,102‌
109,471‌
328,826‌
Total
Services
1,255,111‌
Total
Miscellaneous
Common
Stocks
 4.8% (6)
526,184‌
Total
Common
Stocks
(Cost
$5,344,481)
10,344,548‌
CONVERTIBLE
BONDS
 0.2%
BIOTECHNOLOGY
 0.2%
Other
Biotechnology
 0.2%
Delfi
Diagnostics,
0.00%,
1/29/27,
Acquisition
Date:
12/1/25,
Cost $1,732 (1)(2)(3)
1,732,158‌
1,732‌
Immunocore
Holdings,
2.50%,
2/1/30 
15,469,000‌
13,946‌
Kartos
Therapeutics,
0.00%,
3/4/27,
Acquisition
Date:
3/4/26,
Cost $741 (1)(2)(3)
741,016‌
741‌
Total
Biotechnology
16,419‌
T.
ROWE
PRICE
Health
Sciences
Fund
7
Shares/Par
$
Value
(Cost
and
value
in
$000s)
PRODUCTS
&
DEVICES
 0.0%
Capital
Equipment
 0.0%
RefleXion
Medical,
0.00%,
7/24/26,
Acquisition
Date:
7/28/25,
Cost $239 (1)(2)(3)
239,698‌
657‌
RefleXion
Medical,
15.00%,
7/11/26,
Acquisition
Date:
8/13/25,
Cost $240 (2)(3)
239,698‌
652‌
RefleXion
Medical,
15.00%,
7/11/26,
Acquisition
Date:
8/27/25,
Cost $240 (2)(3)
239,698‌
647‌
Total
Products
&
Devices
1,956‌
Total
Convertible
Bonds
(Cost
$18,661)
18,375‌
CONVERTIBLE
PREFERRED
STOCKS
 3.8%
BIOTECHNOLOGY
 2.1%
Other
Biotechnology
 2.1%
Arbor
Bio,
Series
B,
Acquisition
Date:
10/29/21,
Cost $8,828 (1)
(2)(3)
532,759‌
2,834‌
Arsenal
Biosciences,
Series
C,
Acquisition
Date:
7/9/24,
Cost $13,459 (1)(2)(3)
724,394‌
13,459‌
Avalyn
Pharma,
Series
C-1,
Acquisition
Date:
9/22/23,
Cost $6,178 (1)(2)(3)
8,436,161‌
6,718‌
Avalyn
Pharma,
Series
D,
Acquisition
Date:
4/25/25,
Cost $1,327 (1)(2)(3)
1,666,360‌
1,327‌
Chroma
Medicine,
Series
I,
Acquisition
Date:
10/12/21
-
12/4/24,
Cost $17,211 (1)(2)(3)
7,683,800‌
7,684‌
Delfi
Diagnostics,
Series
A,
Acquisition
Date:
1/12/21
-
4/7/22,
Cost $7,107 (1)(2)(3)
3,426,868‌
13,399‌
Delfi
Diagnostics,
Series
B,
Acquisition
Date:
6/10/22,
Cost $8,980 (1)(2)(3)
1,853,138‌
7,246‌
Endeavor
Bio,
Series
B,
Acquisition
Date:
1/21/22,
Cost $8,808 (1)(2)(3)
1,867,734‌
12,186‌
Endeavor
Bio,
Series
C,
Acquisition
Date:
4/22/24,
Cost $3,195 (1)(2)(3)
489,761‌
3,195‌
FOG
Pharma,
Series
C,
Acquisition
Date:
1/11/21
-
8/2/21,
Cost $6,251 (1)(2)(3)
431,391‌
3,624‌
FOG
Pharma,
Series
D,
Acquisition
Date:
11/17/22,
Cost $6,622 (1)(2)(3)
615,203‌
4,471‌
FOG
Pharma,
Series
E,
Acquisition
Date:
2/29/24
-
1/22/25,
Cost $3,882 (1)(2)(3)
623,217‌
3,842‌
Genesis
Therapeutics,
Series
A,
Acquisition
Date:
11/24/20,
Cost $4,236 (1)(2)(3)
829,412‌
4,236‌
Genesis
Therapeutics,
Series
B,
Acquisition
Date:
8/10/23,
Cost $10,152 (1)(2)(3)
1,987,585‌
10,152‌
T.
ROWE
PRICE
Health
Sciences
Fund
8
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Insitro,
Series
B,
Acquisition
Date:
5/21/20,
Cost $5,505 (1)(2)
(3)
883,580‌
16,162‌
Insitro,
Series
C,
Acquisition
Date:
4/7/21,
Cost $10,762 (1)(2)
(3)
588,382‌
10,762‌
Kailera
Therapeutics,
Series
B,
Acquisition
Date:
10/31/25,
Cost $8,774 (1)(2)(3)
626,703‌
8,774‌
Kartos
Therapeutics,
Series
C,
Acquisition
Date:
8/22/23,
Cost $10,593 (1)(2)(3)
1,873,841‌
10,593‌
Kartos
Therapeutics,
Series
D,
Acquisition
Date:
2/26/25,
Cost $2,904 (1)(2)(3)
513,724‌
2,904‌
Laronde,
Series
B,
Acquisition
Date:
7/28/21,
Cost $32,757 (1)
(2)(3)
1,169,887‌
1,685‌
Obsidian
Therapeutics,
Series
C,
Acquisition
Date:
3/27/24,
Cost $8,821 (1)(2)(3)
4,647,794‌
8,821‌
Odyssey
Therapeutics,
Series
B,
Acquisition
Date:
5/13/22,
Cost $7,048 (1)(2)(3)
1,115,915‌
1,763‌
Odyssey
Therapeutics,
Series
C,
Acquisition
Date:
10/25/23,
Cost $530 (1)(2)(3)
105,905‌
160‌
Odyssey
Therapeutics,
Series
D,
Acquisition
Date:
6/16/25,
Cost $669 (1)(2)(3)
444,487‌
669‌
Parabilis
Medicines,
Series
F,
Acquisition
Date:
1/6/26,
Cost $6,125 (1)(2)(3)
993,688‌
6,125‌
Scribe
Therapeutics,
Series
B,
Acquisition
Date:
3/17/21,
Cost $6,219 (1)(2)(3)
1,027,755‌
6,219‌
Tessera
Therapeutics,
Series
C,
Acquisition
Date:
2/25/22,
Cost $7,915 (1)(2)(3)
674,174‌
3,492‌
Tessera
Therapeutics,
Series
D,
Acquisition
Date:
3/7/25,
Cost $1,979 (1)(2)(3)
381,989‌
1,979‌
Third
Arc
Bio,
Series
A,
Acquisition
Date:
7/16/24
-
1/12/26,
Cost $10,123 (1)(2)(3)
4,810,936‌
10,123‌
Treeline
Biosciences,
Series
A,
Acquisition
Date:
4/9/21
-
9/26/22,
Cost $18,552 (1)(2)(3)
2,370,150‌
17,271‌
Treeline
Biosciences,
Series
A-1,
Acquisition
Date:
10/2/24,
Cost $23,629 (1)(2)(3)
2,744,291‌
19,998‌
Treeline
Biosciences,
Series
A-2,
Acquisition
Date:
8/21/25,
Cost $2,578 (1)(2)(3)
299,448‌
2,182‌
Total
Biotechnology
224,055‌
CONSUMER
NONDURABLES
 0.1%
Biotechnology
 0.0%
Arbor
Bio,
Series
C,
Acquisition
Date:
10/21/24,
Cost $1,324 (1)
(2)(3)
322,096‌
1,714‌
Nutcracker
Therapeutics,
Series
C,
Acquisition
Date:
8/27/21,
Cost $11,050 (1)(2)(3)
1,027,785‌
—‌
1,714‌
T.
ROWE
PRICE
Health
Sciences
Fund
9
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Health
Care
Services
 0.1%
Capsule,
Series
1-D,
Acquisition
Date:
4/7/21,
Cost $12,364 (1)
(2)(3)
853,213‌
862‌
Capsule,
Series
E,
Acquisition
Date:
1/10/23,
Cost $2,658 (1)
(2)(3)
906,656‌
916‌
Color
Health,
Series
D,
Acquisition
Date:
12/17/20,
Cost $11,180 (1)(2)(3)
296,922‌
5,698‌
Color
Health,
Series
D-1,
Acquisition
Date:
1/13/20,
Cost $9,358 (1)(2)(3)
438,696‌
5,913‌
Color
Health,
Series
E,
Acquisition
Date:
10/26/21,
Cost $4,414 (1)(2)(3)
44,149‌
1,810‌
15,199‌
Total
Consumer
Nondurables
16,913‌
FINANCIAL
 0.1%
Investment
Dealers
 0.1%
Seaport
Therapeutics,
Series
B,
Acquisition
Date:
10/18/24,
Cost $11,030 (1)(2)(3)
2,322,209‌
11,030‌
Total
Financial
11,030‌
LIFE
SCIENCES
 0.8%
Life
Sciences
 0.8%
Cellanome,
Series
A,
Acquisition
Date:
12/30/21,
Cost $11,023 (1)(2)(3)
1,993,387‌
17,342‌
Chromacode,
Series
AA,
Acquisition
Date:
5/22/25,
Cost $178 (1)(2)(3)
36,845‌
178‌
Clear
Labs,
Series
C,
Acquisition
Date:
5/13/21,
Cost $13,294 (1)(2)(3)
3,830,773‌
12,120‌
Clear
Labs,
Series
D,
Acquisition
Date:
12/12/24,
Cost $1,183 (1)(2)(3)
379,601‌
1,183‌
DNA
Script,
Series
C,
Acquisition
Date:
12/16/21,
Cost $21,371
(EUR) (1)(2)(3)
25,201‌
2,610‌
Element
Biosciences,
Series
C,
Acquisition
Date:
6/21/21,
Cost $17,704 (1)(2)(3)
861,217‌
5,908‌
Element
Biosciences,
Series
D,
Acquisition
Date:
6/28/24,
Cost $2,207 (1)(2)(3)
281,354‌
1,562‌
Element
Biosciences,
Series
D-1,
Acquisition
Date:
6/28/24,
Cost $2,207 (1)(2)(3)
281,354‌
1,562‌
Lumicks
Tech,
Series
D,
Acquisition
Date:
4/14/21,
Cost $8,875 (1)(2)(3)
4,954‌
2,670‌
Manus
Bio,
Series
One-6,
Acquisition
Date:
3/30/21,
Cost $12,829 (1)(2)(3)
1,223,104‌
3,669‌
National
Resilience,
Series
B,
Acquisition
Date:
10/23/20,
Cost $16,458 (1)(2)(3)
1,204,832‌
26,350‌
T.
ROWE
PRICE
Health
Sciences
Fund
10
Shares/Par
$
Value
(Cost
and
value
in
$000s)
National
Resilience,
Series
C,
Acquisition
Date:
6/9/21,
Cost $18,957 (1)(2)(3)
426,855‌
9,335‌
Total
Life
Sciences
84,489‌
PRODUCTS
&
DEVICES
 0.5%
Capital
Equipment
 0.0%
DeepSight
Technology,
Series
C,
Acquisition
Date:
3/18/26,
Cost $4,379 (1)(2)(3)
342,294‌
4,379‌
Reflexion
Medical,
Series
C,
Acquisition
Date:
4/3/18,
Cost $4,243 (1)(2)(3)
2,507,885‌
3‌
Reflexion
Medical,
Series
D,
Acquisition
Date:
4/3/20,
Cost $2,141 (1)(2)(3)
1,123,437‌
1‌
Reflexion
Medical,
Series
E,
Acquisition
Date:
3/1/22,
Cost $4,403 (1)(2)(3)
1,857,286‌
3‌
Reflexion
Medical,
Series
F,
Acquisition
Date:
11/13/23,
Cost $2,690 (1)(2)(3)
1,794,104‌
2‌
4,388‌
Implants
 0.3%
Kardium,
Series
D-5,
Acquisition
Date:
11/29/18,
Cost $8,574 (1)(2)(3)
8,849,057‌
7,249‌
Kardium,
Series
D-6,
Acquisition
Date:
1/8/21,
Cost $12,516 (1)
(2)(3)
12,320,393‌
10,194‌
Kardium,
Series
D-7,
Acquisition
Date:
6/9/25,
Cost $5,850 (1)
(2)(3)
12,050,573‌
7,799‌
Kardium,
Series
D-8,
Acquisition
Date:
6/6/25,
Cost $4,392 (1)
(2)(3)
6,786,958‌
4,393‌
29,635‌
Other
Products
&
Devices
 0.2%
Galvanize
Therapeutics,
Series
C,
Acquisition
Date:
7/7/25
-
3/20/26,
Cost $7,031 (1)(2)(3)(4)
13,270,470‌
5,441‌
Galvanize
Therapeutics,
Series
C-1,
Acquisition
Date:
7/7/25,
Cost $2,659 (1)(2)(3)(4)
7,721,685‌
3,166‌
Galvanize
Therapeutics,
Series
C-2,
Acquisition
Date:
7/7/25,
Cost $8,988 (1)(2)(3)(4)
26,100,000‌
10,701‌
19,308‌
Total
Products
&
Devices
53,331‌
SERVICES
 0.2%
Information
 0.1%
Cleerly,
Series
C,
Acquisition
Date:
7/8/22,
Cost $6,904 (1)(2)
(3)
586,029‌
10,285‌
10,285‌
T.
ROWE
PRICE
Health
Sciences
Fund
11
Shares/Par
$
Value
(Cost
and
value
in
$000s)
Other
Services
 0.1%
Freenome
Holdings,
Series
B,
Acquisition
Date:
6/24/19,
Cost $7,103 (1)(3)
1,558,570‌
4,550‌
Freenome
Holdings,
Series
C,
Acquisition
Date:
8/14/20,
Cost $6,139 (1)(3)
928,231‌
2,710‌
Freenome
Holdings,
Series
D,
Acquisition
Date:
11/22/21,
Cost $3,971 (1)(3)
526,504‌
1,537‌
Freenome
Holdings,
Series
F,
Acquisition
Date:
1/26/24,
Cost $1,322 (1)(3)
178,707‌
522‌
9,319‌
Providers
 0.0%
Honor
Technology,
Series
D,
Acquisition
Date:
10/16/20,
Cost $7,539 (1)(2)(3)
3,130,941‌
939‌
Honor
Technology,
Series
E,
Acquisition
Date:
9/29/21,
Cost $6,626 (1)(2)(3)
2,095,807‌
629‌
1,568‌
Total
Services
21,172‌
Total
Convertible
Preferred
Stocks
(Cost
$568,853)
410,990‌
PREFERRED
STOCKS
 0.1%
LIFE
SCIENCES
 0.1%
Life
Sciences
 0.1%
Sartorius
(EUR) 
44,309‌
11,087‌
Total
Life
Sciences
11,087‌
Total
Preferred
Stocks
(Cost
$5,956)
11,087‌
SHORT-TERM
INVESTMENTS
 0.3%
Money
Market
Funds
 0.3%
T.
Rowe
Price
Government
Reserve
Fund,
3.71% (4)(7)
38,075,286‌
38,075‌
Total
Short-Term
Investments
(Cost
$38,075)
38,075‌
Total
Investments
in
Securities
 99.4%
(Cost
$5,976,026)
$
10,823,075‌
Other
Assets
Less
Liabilities
0.6%
62,364‌
Net
Assets
100.0%
$
10,885,439‌
Shares/Par
are
denominated
in
U.S.
dollars
unless
otherwise
noted.
(1)
Non-income
producing
(2)
Level
3
in
fair
value
hierarchy.
T.
ROWE
PRICE
Health
Sciences
Fund
12
.
.
.
.
.
.
.
.
.
.
(3)
Security
cannot
be
offered
for
public
resale
without
first
being
registered
under
the
Securities
Act
of
1933
and
related
rules
("restricted
security").
Acquisition
date
represents
the
day
on
which
an
enforceable
right
to
acquire
such
security
is
obtained
and
is
presented
along
with
related
cost
in
the
security
description.
The
fund
may
have
registration
rights
for
certain
restricted
securities.
Any
costs
related
to
such
registration
are
generally
borne
by
the
issuer.
The
aggregate
value
of
restricted
securities
(excluding
144A
holdings)
at
period
end
amounts
to
$485,360
and
represents
4.5%
of
net
assets.
(4)
Affiliated
Companies
(5)
All
or
a
portion
of
the
position
represents
an
unfunded
commitment;
a
liability
to
fund
the
commitment
has
been
recognized.
The
fund's
total
unfunded
commitment
at
March
31,
2026,
was
$4,382
and
was
valued
at
$4,326
(0.0%
of
net
assets).
(6)
The
identity
of
certain
securities
has
been
concealed
to
protect
the
fund
while
it
completes
a
purchase
or
selling
program
for
the
securities.
(7)
Seven-day
yield
ADR
American
Depositary
Receipts
AUD
Australian
Dollar
CDI
CHESS
or
CREST
Depositary
Interest
CHF
Swiss
Franc
EC
Escrow
CUSIP;
represents
a
beneficial
interest
in
a
residual
pool
of
assets;
the
amount
and
timing
of
future
distributions,
if
any,
is
uncertain;
when
presented,
interest
rate
and
maturity
date
are
those
of
the
original
security.
EUR
Euro
HKD
Hong
Kong
Dollar
JPY
Japanese
Yen
PIPE
Private
Investment
in
Public
Equity
SPAC
Special
Purpose
Acquisition
Company
T.
ROWE
PRICE
Health
Sciences
Fund
13
AFFILIATED
COMPANIES
($000s)
The
fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
1940
Act,
an
affiliated
company
is
one
in
which
the
fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
that
is
under
common
ownership
or
control.
The
following
securities
were
considered
affiliated
companies
for
all
or
some
portion
of
the
three
months
ended
March
31,
2026.
Net
realized
gain
(loss),
investment
income,
change
in
net
unrealized
gain/loss,
and
purchase
and
sales
cost
reflect
all
activity
for
the
period
then
ended.
Affiliate
Net
Realized
Gain
(Loss)
Change
in
Net
Unrealized
Gain/Loss
Investment
Income
Galvanize
Therapeutics,
Series
$
—‌
$
(1,591‌)
$
—‌
Galvanize
Therapeutics,
Series
C-1 
—‌
(925‌)
—‌
Galvanize
Therapeutics,
Series
C-2 
—‌
(3,127‌)
—‌
Tenax
Therapeutics ^^
7,245‌
8,388‌
—‌
T.
Rowe
Price
Government
Reserve
Fund,
3.71%
—‌
—‌
418‌
Affiliates
not
held
at
period
end
14,901‌
(15,498‌)
—‌
Totals
$
22,146‌#
$
(12,753‌)
$
418‌+
T.
ROWE
PRICE
Health
Sciences
Fund
14
The
accompanying
notes
are
an
integral
part
of
this
Portfolio
of
Investments.
AFFILIATED
COMPANIES
(CONTINUED)
($000s)
Supplementary
Investment
Schedule
Affiliate
Value
12/31/25
Purchase
Cost
Sales
Cost
Value
3/31/26
Bluejay
Therapeutics,
Series
$
31,006‌
$
—‌
$
16,506‌
$
—‌
Bluejay
Therapeutics,
Series
C-1 
2,133‌
—‌
1,135‌
—‌
Galvanize
Therapeutics,
Series
4,219‌
2,813‌
—‌
5,441‌
Galvanize
Therapeutics,
Series
C-1 
4,091‌
—‌
—‌
3,166‌
Galvanize
Therapeutics,
Series
C-2 
13,828‌
—‌
—‌
10,701‌
Tenax
Therapeutics ^^
27,162‌
9,391‌
4,270‌
40,671‌
T.
Rowe
Price
Government
Reserve
Fund,
3.71%
16,957‌
 ¤
 ¤
38,075‌
Total
$
98,054‌^
#
Capital
gain
distributions
from
underlying
Price
funds
represented
$0
of
the
net
realized
gain
(loss).
+
Investment
income
comprised
$418
of
dividend
income
and
$0
of
interest
income.
¤
Purchase
and
sale
information
not
shown
for
cash
management
funds.
^
The
cost
basis
of
investments
in
affiliated
companies
was
$68,140.
^^
Includes
previously
reported
affiliates
Tenax
Therapeutics,
Warrants;
Tenax
Therapeutics,
Warrants,
8/29/29
acquired
through
a
corporate
action.
T.
ROWE
PRICE
Health
Sciences
Fund
Unaudited
Notes
to
Portfolio
of
Investments
15
T.
Rowe
Price
Health
Sciences
Fund,
Inc. (the
corporation)
is
registered
under
the
Investment
Company
Act
of
1940
(the
1940
Act). The
Health
Sciences
Fund,
Inc.
(the
fund)
is an open-end
management
investment
company
established
by
the
corporation
and
follows
accounting
and
reporting
guidance
of
the
Financial
Accounting
Standards
Board
Accounting
Standards
Codification
Topic
946.
The
accompanying
Portfolio
of
Investments
was
prepared
in
accordance
with
accounting
principles
generally
accepted
in
the
United
States
of
America
(GAAP).
For
additional
information
on
the
fund’s
significant
accounting
policies
and
investment
related
disclosures,
please
refer
to
the
fund’s most
recent
semiannual
or
annual
shareholder
report
and
its
prospectus.
VALUATION 
Fair
Value
  The
fund’s
financial
instruments
are
valued
at
the
close
of
the
New
York
Stock
Exchange
(NYSE),
normally
4
p.m.
Eastern
time,
each
day
the
NYSE
is
open
for
business,
and
are
reported
at
fair
value,
which
GAAP
defines
as
the
price
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date. The fund’s
Board
of
Directors
(the
Board)
has
designated
T.
Rowe
Price
Associates,
Inc.
as
the
fund’s
valuation
designee
(Valuation
Designee).
Subject
to
oversight
by
the
Board,
the
Valuation
Designee
performs
the
following
functions
in
performing
fair
value
determinations:
assesses
and
manages
valuation
risks;
establishes
and
applies
fair
value
methodologies;
tests
fair
value
methodologies;
and
evaluates
pricing
vendors
and
pricing
agents.
The
duties
and
responsibilities
of
the
Valuation
Designee
are
performed
by
its
Valuation
Committee. The
Valuation
Designee provides
periodic
reporting
to
the
Board
on
valuation
matters.
Various
valuation
techniques
and
inputs
are
used
to
determine
the
fair
value
of
financial
instruments.
GAAP
establishes
the
following
fair
value
hierarchy
that
categorizes
the
inputs
used
to
measure
fair
value:
Level
1
quoted
prices
(unadjusted)
in
active
markets
for
identical
financial
instruments
that
the
fund
can
access
at
the
reporting
date
Level
2
inputs
other
than
Level
1
quoted
prices
that
are
observable,
either
directly
or
indirectly
(including,
but
not
limited
to,
quoted
prices
for
similar
financial
instruments
in
active
markets,
quoted
prices
for
identical
or
similar
financial
instruments
in
inactive
markets,
interest
rates
and
yield
curves,
implied
volatilities,
and
credit
spreads)
T.
ROWE
PRICE
Health
Sciences
Fund
16
Level
3
unobservable
inputs
(including
the Valuation
Designee’s assumptions
in
determining
fair
value)
Observable
inputs
are
developed
using
market
data,
such
as
publicly
available
information
about
actual
events
or
transactions,
and
reflect
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
Unobservable
inputs
are
those
for
which
market
data
are
not
available
and
are
developed
using
the
best
information
available
about
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
GAAP
requires
valuation
techniques
to
maximize
the
use
of
relevant
observable
inputs
and
minimize
the
use
of
unobservable
inputs.
When
multiple
inputs
are
used
to
derive
fair
value,
the
financial
instrument
is
assigned
to
the
level
within
the
fair
value
hierarchy
based
on
the
lowest-level
input
that
is
significant
to
the
fair
value
of
the
financial
instrument.
Input
levels
are
not
necessarily
an
indication
of
the
risk
or
liquidity
associated
with
financial
instruments
at
that
level
but
rather
the
degree
of
judgment
used
in
determining
those
values.
Valuation
Techniques 
Equity
securities,
including
exchange-traded
funds, listed
or
regularly
traded
on
a
securities
exchange
or
in
the
over-the-
counter
(OTC)
market
are
valued
at
the
last
quoted
sale
price
or,
for
certain
markets,
the
official
closing
price
at
the
time
the
valuations
are
made.
OTC
Bulletin
Board
securities
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices.
A
security
that
is
listed
or
traded
on
more
than
one
exchange
is
valued
at
the
quotation
on
the
exchange
determined
to
be
the
primary
market
for
such
security.
Listed
securities
not
traded
on
a
particular
day
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices
for
domestic
securities
and
the
last
quoted
sale
or
closing
price
for
international
securities.
The
last
quoted
prices
of
non-U.S.
equity
securities
may
be
adjusted
to
reflect
the
fair
value
of
such
securities
at
the
close
of
the
NYSE,
if
the Valuation
Designee
determines
that
developments
between
the
close
of
a
foreign
market
and
the
close
of
the
NYSE
will
affect
the
value
of
some
or
all
of
its portfolio
securities.
Each
business
day,
the
Valuation
Designee uses
information
from
outside
pricing
services
to
evaluate
the
quoted
prices
of
portfolio
securities
and,
if
appropriate,
decides whether
it
is
necessary
to
adjust
quoted
prices
to
reflect
fair
value
by
reviewing
a
variety
of
factors,
including
developments
in
foreign
markets,
the
performance
of
U.S.
securities
markets,
and
the
performance
of
instruments
trading
in
U.S.
markets
that
represent
foreign
securities
and
baskets
of
foreign
securities. The Valuation
Designee
uses
outside
pricing
services
to
provide
it
with
quoted
prices
and
information
to
evaluate
or
adjust
T.
ROWE
PRICE
Health
Sciences
Fund
17
those
prices.
The Valuation
Designee
cannot
predict
how
often
it
will
use
quoted
prices
or how
often
it
will
determine
it
necessary
to
adjust
those
prices
to
reflect
fair
value.
Debt
securities
are
generally traded
in
the over-the-counter
(OTC)
market
and
are
valued
at
prices
furnished
by
independent
pricing
services
or
by
broker
dealers
who
make
markets
in
such
securities.
When
valuing
securities,
the
independent
pricing
services
consider
factors
such
as,
but
not
limited
to,
the
yield
or
price
of
bonds
of
comparable
quality,
coupon,
maturity,
and
type,
as
well
as
prices
quoted
by
dealers
who
make
markets
in
such
securities.
Investments
denominated
in
foreign
currencies
are
translated
into
U.S.
dollar
values
each
day
at
the
prevailing
exchange
rate,
using
the
mean
of
the
bid
and
asked
prices
of
such
currencies
against
U.S.
dollars
as
provided
by
an
outside
pricing
service.
Investments
in
mutual
funds
are
valued
at
the
mutual
fund’s
closing
NAV
per
share
on
the
day
of
valuation.
Investments
for
which
market
quotations are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
as
determined
in
good
faith
by
the
Valuation
Designee.
The
Valuation
Designee
has
adopted
methodologies
for
determining
the
fair
value
of
investments
for
which
market
quotations
are
not
readily
available
or
deemed
unreliable,
including
the
use
of
other
pricing
sources.
Factors
used
in
determining
fair
value
vary
by
type
of
investment
and
may
include
market
or
investment
specific
considerations.
The
Valuation
Designee typically
will
afford
the
greatest
weight
to
actual
prices
in
arm’s
length
transactions,
to
the
extent
they
represent
orderly
transactions
between
market
participants,
transaction
information
can
be
reliably
obtained,
and
prices
are
deemed
representative
of
fair
value.
However,
the
Valuation
Designee may
also
consider
other
valuation
methods
such
as
market-based
valuation
multiples;
a
discount
or
premium
from
market
value
of
a
similar,
freely
traded
security
of
the
same
issuer;
discounted
cash
flows;
yield
to
maturity;
or
some
combination.
Fair
value
determinations
are
reviewed
on
a
regular
basis.
Because
any
fair
value
determination
involves
a
significant
amount
of
judgment,
there
is
a
degree
of
subjectivity
inherent
in
such
pricing
decisions. Fair
value
prices
determined
by
the
Valuation
Designee could
differ
from
those
of
other
market
participants,
and
it
is
possible
that
the
fair
value
determined
for
a
security
may
be
materially
different
from
the
value
that
could
be
realized
upon
the
sale
of
that
security.
T.
ROWE
PRICE
Health
Sciences
Fund
18
Valuation
Inputs
  The
following
table
summarizes
the
fund’s
financial
instruments,
based
on
the
inputs
used
to
determine
their
fair
values
on
March
31,
2026
(for
further
detail
by
category,
please
refer
to
the
accompanying
Portfolio
of
Investments): 
Following
is
a
reconciliation
of
the
fund’s
Level
3
holdings
for
the
period ended
March
31,
2026.
Gain
(loss)
reflects
both
realized
and
change
in
unrealized
gain/
loss
on
Level
3
holdings
during
the
period,
if
any.
The
change
in
unrealized
gain/
loss
on
Level
3
instruments
held
at
March
31,
2026,
totaled $(8,990,000) for
the
period ended
March
31,
2026.
In
accordance
with
GAAP,
the
following
table
provides
quantitative
information
about
significant
unobservable
inputs
used
to
determine
the
fair
valuations
of
the
fund’s
Level
3
assets,
by
class
of
financial
instrument.
Because
the
Valuation
Designee considers
a
wide
variety
of
factors
and
($000s)
Level
1
Level
2
Level
3
Total
Value
Assets
Common
Stocks
$
10,038,345‌
$
298,665‌
$
7,538‌
$
10,344,548‌
Convertible
Bonds
—‌
13,946‌
4,429‌
18,375‌
Convertible
Preferred
Stocks
—‌
9,319‌
401,671‌
410,990‌
Preferred
Stocks
—‌
11,087‌
—‌
11,087‌
Short-Term
Investments
38,075‌
—‌
—‌
38,075‌
Total
$
10,076,420‌
$
333,017‌
$
413,638‌
$
10,823,075‌
($000s)
Beginning
Balance
12/31/25
Gain
(Loss)
During
Period
Total
Purchases
Total
Sales
Ending
Balance
3/31/26
Investment
in
Securities
Common
Stocks
$
8,795‌
$
(2,546‌)
$
1,289‌
$
—‌
$
7,538‌
Convertible
Bonds
2,861‌
827‌
741‌
—‌
4,429‌
Convertible
Preferred
Stocks
481,196‌
3,632‌
14,615‌
(97,772‌)
401,671‌
Total
$
492,852‌
$
1,913‌
$
16,645‌
$
(97,772‌)
$
413,638‌
T.
ROWE
PRICE
Health
Sciences
Fund
19
inputs,
both
observable
and
unobservable,
in
determining
fair
values,
the
unobservable
inputs
presented
do
not
reflect
all
inputs
significant
to
the
fair
value
determination.
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Common
Stocks
$
7,538‌
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
uncertainty
5%
-
100%
8%
Decrease
Discount
for
dilution
15%
15%
Decrease
Market
comparable
Enterprise
value
to
sales
multiple
2.0x
2.0x
Increase
Enterprise
value
to
gross
profit
multiple
4.9x
4.9x
Increase
Discount
for
uncertainty
100%
100%
Decrease
Discount
for
lack
of
marketability
10%
10%
Decrease
Convertible
Bonds
$
4,429‌
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Private
company
valuation
—#
—#
—#
Convertible
Preferred
Stocks
$
401,671‌
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
T.
ROWE
PRICE
Health
Sciences
Fund
20
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Private
company
valuation
—#
—#
—#
Discount
for
uncertainty
50%
50%
Decrease
Discount
for
dilution
15%
15%
Decrease
Market
comparable
Premium
for
liquidation
preference
—#
—#
—#
Probability
for
potential
outcome
10%
-
55%
33%
Increase
Enterprise
value
to
sales
multiple
0.8x
-
11.6x
5.7x
Increase
Sales
growth
rate
0%
-
127%
61%
Increase
Enterprise
value
to
gross
profit
multiple
6.1x
6.1x
Increase
Enterprise
value
to
EBITDA
multiple
10.2x
-
10.3x
10.3x
Increase
EBITDA
growth
rate
2%
2%
Increase
Cost
of
capital
25%
-
45%
29%
Decrease
Discount
for
lack
of
recoverability
—#
—#
—#
Discount
to
public
company
multiples
17%
-
62%
43%
Decrease
T.
ROWE
PRICE
Health
Sciences
Fund
21
+
Valuation
techniques
may
change
in
order
to
reflect the
Valuation
Designee’s
judgment
of
current
market
participant
assumptions. 
*
Unobservable
inputs
were
weighted
by
the
relative
fair
value
of
the
instruments.
**
Represents
the
directional
change
in
the
fair
value
of
the
Level
3
investment(s)
that
would
have
resulted
from
an
increase
in
the
corresponding
input
at
period
end.
A
decrease
in
the
unobservable
input
would
have
had
the
opposite
effect.
Significant
increases
and
decreases
in
these
inputs
in
isolation
could
result
in
significantly
higher
or
lower
fair
value
measurements.
#
No
quantitative
unobservable
inputs
significant
to
the
valuation
technique
were
created
by
the
Valuation
Designee.
OTHER
MATTERS 
Unpredictable environmental,
political,
social
and
economic
events,
including
but
not
limited
to,
environmental
or
natural
disasters,
war
and
conflict,
terrorism,
geopolitical
and
regulatory
developments
(including
trading
and
tariff
arrangements),
and
public
health
epidemics
or
threats,
may
significantly
affect
the
economy
and
the
markets
and
issuers
in
which
a
fund
invests.
The
extent
and
duration
of
such
events
and
resulting
market
disruptions
cannot
be
predicted.
These
and
other
similar
events
may
cause
instability
across
global
markets,
including
reduced
liquidity
and
disruptions
in
trading
markets,
while
some
events
may
affect
certain
geographic
regions,
countries,
sectors,
and
industries
more
significantly
than
others,
and
exacerbate
other
pre-
existing
political,
social,
and
economic
risks.
The
fund’s
performance
could
be
negatively
impacted
if
the
value
of
a
portfolio
holding
were
harmed
by
these
or
such
events.
F114-054Q1
03/26
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Discount
for
uncertainty
100%
100%
Decrease
Discount
for
lack
of
marketability
10%
10%
Decrease